Health Economics Policy and Law最新文献

Constructing a single market for pharmaceuticals in the EU: what's the price? 在欧盟建立单一药品市场：价格是多少？

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-04-01 Epub Date: 2025-10-27 DOI: 10.1017/S1744133125100236

Tineke Kleinhout-Vliek, Susi Geiger, Rob Hagendijk, Eva Hilberg, Paul Martin, Katrina Perehudoff, Sarah Wadmann, Jakob Wested

引用次数: 0

A European vision for telemedicine in cancer care: policy and patient perspectives from the eCAN Joint Action. 欧洲癌症护理远程医疗愿景：来自eCAN联合行动的政策和患者观点。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-04-01 Epub Date: 2026-01-30 DOI: 10.1017/S1744133125100273

Tugce Schmitt, Katharina Habimana, Anita Gottlob, Claudia Habl, Christina Plomariti, Anastasia Farmaki, Panagiotis Bogiatzidis, Victoria Leclercq, Marie Delnord, Marc Van den Bulcke

{"title":"A European vision for telemedicine in cancer care: policy and patient perspectives from the eCAN Joint Action.","authors":"Tugce Schmitt, Katharina Habimana, Anita Gottlob, Claudia Habl, Christina Plomariti, Anastasia Farmaki, Panagiotis Bogiatzidis, Victoria Leclercq, Marie Delnord, Marc Van den Bulcke","doi":"10.1017/S1744133125100273","DOIUrl":"10.1017/S1744133125100273","url":null,"abstract":"Telemedicine is increasingly playing a vital role in European health systems, offering great potential for improving healthcare access and outcomes. Funded between September 2022 and December 2024, the Joint Action 'Strengthening eHealth including telemedicine and remote monitoring for health care systems for CANcer prevention and care' (eCAN JA) provided evidence-base for person-centred implementation of telemedicine services among cancer patients in the European Union (EU). Through a mixed-method approach, this foresight study gathered insights from key decision-makers in 14 EU Member States and eight cancer patient associations via two surveys and a joint workshop, conducted within the Sustainability Work Package (WP4) of the eCAN JA. Our results show that EU Member States and cancer patients view telemedicine as a useful and complementary tool, however, not as a replacement for in-person services for cancer care. The policy recommendations from our study can be summarised as follows: (i) develop legal frameworks to complement in-person care with telemedicine; (ii) improve digital literacy and information technology infrastructure while ensuring privacy and health equity; and (iii) engage patients in the co-design of telemedicine services. Implementing these recommendations will enhance the integration of telemedicine into cancer care in Europe.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"232-250"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Priority setting for health equality - searching for an ethical framework. 确定卫生平等的优先事项——寻找道德框架。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-04-01 Epub Date: 2025-10-27 DOI: 10.1017/S1744133125100224

Sabrina Germain, Christopher Newdick

引用次数: 0

The role of European HTA agencies in relation to the governance of medical technologies: a discourse analysis of academic literature. 欧洲HTA机构在医疗技术治理方面的作用：学术文献的话语分析。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-04-01 Epub Date: 2025-12-29 DOI: 10.1017/S1744133125100339

Renée Michels, Diana Delnoij, Wichor Bramer, Bert de Graaff

{"title":"The role of European HTA agencies in relation to the governance of medical technologies: a discourse analysis of academic literature.","authors":"Renée Michels, Diana Delnoij, Wichor Bramer, Bert de Graaff","doi":"10.1017/S1744133125100339","DOIUrl":"10.1017/S1744133125100339","url":null,"abstract":"How the role of health technology assessment (HTA) agencies in relation to medical technologies (MedTech) is framed in the literature reflects and influences governance, shaping perceptions and guiding decisions. We identify different academic discourses to advance MedTech policy debates, in light of several factors potentially influencing this role. This is the first time that discourse on the role of HTA agencies in relation to MedTech has been reviewed. We conducted a comprehensive search, screened for eligibility, and synthesised findings using discourse analysis. 119 articles were included, from which 5 discourses were constructed. The first discourse describes the HTA agency as an independent evaluator of appropriate evidence for all health technologies. The second discourse explicitly categorises MedTech as separate from pharmaceuticals and expands the role of evaluator to include encouraging evidence generation for MedTech. The third discourse moves away from the role of independent evaluator and describes the HTA agency as a convenor of all stakeholder perspectives, using an experimental approach. The fourth and fifth discourses critically reflect on the role of HTA agencies, the fourth on their level of normative reflection and the fifth on their level of nuanced, clinical expertise. We conclude with recommendations for policy and research.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"214-231"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond market entry: law, evidence, and the politics of value in European health system governance. 超越市场进入：欧洲卫生系统治理中的法律、证据和价值政治。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-04-01 Epub Date: 2026-05-04 DOI: 10.1017/S1744133126100462

Rocco Friebel, Iris Wallenburg

引用次数: 0

Constructing effectiveness as a general legal principle of public healthcare systems: comparative insights from France, Germany, and England. 作为公共医疗体系一般法律原则的有效性构建：来自法国、德国和英国的比较见解。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-04-01 Epub Date: 2026-02-04 DOI: 10.1017/S1744133126100371

Irene Domenici, Christian Günther, Ulrich Becker

{"title":"Constructing effectiveness as a general legal principle of public healthcare systems: comparative insights from France, Germany, and England.","authors":"Irene Domenici, Christian Günther, Ulrich Becker","doi":"10.1017/S1744133126100371","DOIUrl":"10.1017/S1744133126100371","url":null,"abstract":"In public healthcare systems, effectiveness is a central requirement for determining which services should be offered and reimbursed. Yet, due to its technical nature and to the need for specification through specialised bodies, the nature of this principle remains underexplored. This article bridges the gap by conducting a comparative analysis of effectiveness' operation in three distinct healthcare systems: Germany, France, and England. We argue that effectiveness can be recognised as a foundational legal principle governing reimbursement decisions, revealing a substantive and a formal dimension. Substantively, effectiveness requires a consideration of an intervention's ability to bring about a clinical benefit, accounting both for its desired outcomes and its risks. The applied evidentiary standard calls for a careful scrutiny of the available scientific evidence, as well as the state of medical knowledge. The exceptions to this standard are extremely limited and do not undermine the validity of the wider principle. Formally, the article emphasises the central role that administrative authorities conducting Health Technology Assessment (HTA) play, with delegated decisions ranging from the definition of the applicable evidentiary standards to the issuing of binding guidelines. It is argued that mechanisms must be put in place to ensure these bodies' expertise, independence, and transparency.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"137-155"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic literature review of real-world evidence (RWE) on post-market assessment of medical devices. 对医疗器械上市后评估的真实世界证据（RWE）进行系统的文献综述。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-04-01 Epub Date: 2025-01-13 DOI: 10.1017/S1744133124000148

Stefania Manetti, Elisa Guidotti, Federico Vola, Milena Vainieri

{"title":"A systematic literature review of real-world evidence (RWE) on post-market assessment of medical devices.","authors":"Stefania Manetti, Elisa Guidotti, Federico Vola, Milena Vainieri","doi":"10.1017/S1744133124000148","DOIUrl":"10.1017/S1744133124000148","url":null,"abstract":"The increasing use of real-world evidence (RWE) and real-world data (RWD) to assess post-market medical devices (MDs) might satisfy the urgent need for data sharing and traceability. This study sought to (i) get an overview of current practice in post-market assessments of MDs reporting on RWE/RWD; (ii) draw policy recommendations for governments and health organisations and identify a research agenda for scholars.A systematic review was undertaken until February 2024 following the PRISMA guidelines. Original peer-reviewed articles in English and incorporating RWE/RWD into any sort of post-market assessment strategy for an MD were included and their reference lists manually checked. A narrative synthesis was employed to describe evidence retrieved.Totally, 145 research articles were identified. Administrative databases were mostly utilised; clinical and/or economic evidence gathered in a short/medium time horizon the most frequently reported; other evidence types (e.g., organisational) underreported; patient perspectives rarely incorporated; the innovation complexity of MDs relatively low.To our knowledge, this study is the first in its kind to provide a comprehensive picture of how non-randomised evidence has been used when assessing MDs working in real-life conditions. The implications of this review might help health policy scholars in addressing the avenues for research in RWE for MDs and policy-makers to better understand the risks and benefits of medium and long-term use of MDs alongside clinical practice and make more informed decisions about adoption and use.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"181-213"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reimbursement prices of new, innovative medicines in Germany: a comparison of negotiation and cost-effectiveness analysis. 德国创新新药报销价格：谈判与成本效益分析的比较。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-04-01 Epub Date: 2025-01-07 DOI: 10.1017/S1744133124000288

Afschin Gandjour

{"title":"Reimbursement prices of new, innovative medicines in Germany: a comparison of negotiation and cost-effectiveness analysis.","authors":"Afschin Gandjour","doi":"10.1017/S1744133124000288","DOIUrl":"https://doi.org/10.1017/S1744133124000288","url":null,"abstract":"This study aimed to compare reimbursement prices for new, innovative non-orphan drugs in Germany based on price negotiation and cost-effectiveness analysis, using the efficiency frontier (EF) approach and cost-utility analysis (CUA). For the EF, the next effective intervention and no intervention were used as comparators. Three pairwise comparisons were conducted: negotiation vs EF, CUA vs EF and negotiation vs CUA. For the comparison between negotiation and EF, relative risk reductions for a given added health benefit were assigned, and resulting price premiums were determined using an empirical estimate from the literature and a conceptual model. The difference between CUA vs EF was determined based on an aggregation rule and thresholds for CUA based on the average and marginal cost-effectiveness of the health care system. The difference between negotiation and CUA was determined through an indirect comparison. Price premiums based on negotiation are approximately 10-40 per cent higher than those based on EF using no intervention as a comparator. Furthermore, price premiums based on CUA (threshold at system-average cost-effectiveness) are approximately 25-50 per cent higher than those based on EF using no intervention as a comparator. The indirect comparison predicts that price premiums based on CUA (threshold at system-average cost-effectiveness) are approximately 10-15 per cent higher than those based on negotiation. For a threshold set at system-marginal cost-effectiveness, price premiums based on CUA are more than threefold higher than those based on negotiation. In the German health care system, CUA with a threshold set at system-average or system-marginal cost-effectiveness is predicted to yield higher reimbursement prices than price negotiations or the EF approach based on no intervention as a comparator.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":"21 2","pages":"156-167"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147822091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does elderly care suppress women's fertility intentions? Quasi-experimental evidence from China's home and community-based services reform. 老年护理是否抑制了女性的生育意愿？来自中国家庭和社区服务改革的准实验证据。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-03-31 DOI: 10.1017/S1744133126100449

Zhiying Li, Longhua Zheng, Yunhui Wang

{"title":"Does elderly care suppress women's fertility intentions? Quasi-experimental evidence from China's home and community-based services reform.","authors":"Zhiying Li, Longhua Zheng, Yunhui Wang","doi":"10.1017/S1744133126100449","DOIUrl":"https://doi.org/10.1017/S1744133126100449","url":null,"abstract":"China's recent expansion of Home- and Community-Based Services (HCBS) may influence fertility intentions among women of childbearing age. Using data from the China Labor-force Dynamics Survey (CLDS, 2014-2018) and a multi-period difference-in-differences (DID) design, we examine the effect of HCBS reforms on women's fertility expectations and explore the channels through which these reforms operate. Our results show that HCBS expansion significantly reduces fertility intentions, with an average decline of approximately 0.12 children per woman. The effect is stronger among women with siblings, those who already have children, rural residents, and women in their prime childbearing years (aged 25-34 years). Mechanism analysis indicates that this reduction is mediated by increased perceived community safety, greater participation in pension insurance, and higher economic satisfaction. These findings suggest that elderly care policies can shape reproductive decisions, highlighting the need for integrated strategies that address both ageing and fertility concerns in China.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"1-19"},"PeriodicalIF":3.3,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147582511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Policy shift toward mandatory premarital screening in a Middle Eastern country: agenda- setting through the lens of Kingdon's multiple streams framework. 中东国家向强制性婚前检查的政策转变：通过金登的多流框架的镜头设定议程。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2026-03-31 DOI: 10.1017/S1744133126100450

Zainab Al Kindi, Joshua Muliira

{"title":"Policy shift toward mandatory premarital screening in a Middle Eastern country: agenda- setting through the lens of Kingdon's multiple streams framework.","authors":"Zainab Al Kindi, Joshua Muliira","doi":"10.1017/S1744133126100450","DOIUrl":"https://doi.org/10.1017/S1744133126100450","url":null,"abstract":"Premarital screening policies are increasingly adopted to prevent hereditary disorders in populations with high consanguinity. In Oman, a Middle Eastern country with significant sickle cell disease prevalence, the shift toward mandatory premarital screening emerged through a strategic policy process influenced by cultural, tribal, and religious values. In this context, premarital screening offers a critical opportunity for early detection and informed reproductive decision-making. This paper provides an explanatory analysis of the agenda-setting process that enabled the formal adoption of compulsory premarital screening for genetic disorders, using Kingdon's Multiple Streams Framework (MSF) as an analytical lens. The analysis demonstrates how hereditary blood disorders, in particular Sickle cell disease (SCD), transitioned from a socially normalised condition to a recognised public health and socioeconomic problem, and how a technically feasible and ethically sensitive policy solution was advanced. Oman's case illustrates how preventive health policies targeting socially sensitive issues can gain traction through stream convergence, and incremental reframing.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"1-7"},"PeriodicalIF":3.3,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147582451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0